Accelerate Diagnostics, Inc. (AXDX)

Market Cap	29.05M
Revenue (ttm)	11.91M
Net Income (ttm)	-53.45M
Shares Out	25.04M
EPS (ttm)	-2.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,417
Open	1.190
Previous Close	1.190
Day's Range	1.140 - 1.236
52-Week Range	0.730 - 4.410
Beta	0.55
Analysts	Hold
Price Target	1.00 (-13.79%)
Earnings Date	Nov 7, 2024

About AXDX

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic sus...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 18, 1996
• Employees: 134
• Stock Exchange: NASDAQ
• Ticker Symbol: AXDX
• Website: https://acceleratediagnostics.com

Financial Performance

In 2023, Accelerate Diagnostics's revenue was $12.06 million, a decrease of -5.43% compared to the previous year's $12.75 million. Losses were -$61.62 million, -1.40% less than in 2022.

Analyst Forecast

According to one analyst, the rating for AXDX stock is "Hold" and the 12-month stock price forecast is $1.0.

Price Target

$1.0

(-13.79% downside)

Analyst Consensus: Hold